In Less Than A Month, Urine Protein Dropped From 0.7g To 0.3g. The Kidney Patient Did The Right Thing!

Urine protein and hematuria are long-term pains for IgA nephropathy patients. The ideal urine protein control target for IgA nephropathy is <0.3g/24h, and the less hematuria, the better. However, how to control proteinuria and hematuria is still a problem. The traditional standard treatment method is to control hypertension, reduce the burden on the glomeruli, and then reduce proteinuria and hematuria. However, the cause of IgA nephropathy is IgA after all, and the precise cause-targeted treatment of IgA is the greatest blessing for kidney patients.

Click to Cistanche for kidney disease

IgA nephropathy is an immune-mediated progressive disease. At present, the "quadruple hit" theory is used internationally to explain the pathogenesis of IgA nephropathy, namely: ① Abnormal intestinal mucosal immune regulation; ② Increased production of Gd-IgA1 derived from mucosal B cells in the Peyer's lymph nodes at the end of the ileum is considered to be the source and key to the disease; ③ The specific and pathogenic immune complexes formed thereby; ④ Deposition in the glomerular mesangium leads to glomerular damage, which in turn damages the renal tubules, leading to hematuria, proteinuria, renal function damage and other conditions. The development of IgA nephropathy treatment drugs can be roughly divided into two stages. Since IgA nephropathy was first described in 1968, systemic steroid hormones and renin-angiotensin system inhibitors (RASi) have been found to be beneficial to IgA nephropathy patients, and then KDIGO issued the first IgA nephropathy guidelines in 2012. However, no drug specifically for the treatment of IgA nephropathy has been available.

Reshaping the new treatment pattern of IgA nephropathy

In 2022, budesonide-targeted sustained-release capsules were approved for marketing by the US FDA as the first causal treatment drug for IgA nephropathy and approved for marketing by the China National Drug Administration in 2023. This is the first drug that directly hits the cause of IgA nephropathy in more than 50 years since IgA nephropathy was first described, which completely reshaped the new treatment pattern of IgA nephropathy. The NefIgArd study showed that during the entire 2-year study period, budesonide-targeted sustained-release capsules were treated for 9 months on the basis of supportive treatment, which significantly delayed the decline in eGFR by 66%, and delayed the progression of the disease to renal failure by 12.8 years. In addition, Nefecon® gave good efficacy and safety data in the Phase III clinical study NefIgArd. It can not only reduce urine protein, reduce the risk of hematuria, and delay renal failure, but also the related adverse reactions are safe and controllable. Compared with a series of serious adverse reactions such as infection, gastrointestinal bleeding, new diabetes, and abnormal bone metabolism caused by long-term use of hormone drugs, this can be said to be a huge improvement, which not only reduces concomitant medication and rescue medication but also saves treatment costs.

The efficacy of kidney patients is significant

Since budesonide targeted sustained-release capsules (Nefecon®) can be applied for medication in mainland my country, many IgA kidney patients have benefited. The following is a share of the indicator changes of a kidney patient who is currently taking medication (personal information has been coded). In the comparison of the test reports of this kidney patient from June 18 to July 12, 2024, we can see that: the 24-hour urine protein quantification dropped from 755.45mg/24h to 303.48mg/24h

The creatinine value dropped from 204μmoI/L to 151.9μmoI/L

Within less than a month of medication, a relatively significant treatment effect was achieved. I am sincerely happy and relieved for the kidney patient. At the same time, it is recommended that patients who have been diagnosed with IgA nephropathy, if conditions permit, join the budesonide-targeted sustained-release capsule treatment as soon as possible to inhibit or reverse the disease progression at an early stage and improve the quality of life

How Does Cistanche Treat Kidney Disease?

Cistanche is a traditional Chinese herbal medicine used for centuries to treat various health conditions, including kidney disease. It is derived from the dried stems of Cistanche deserticola, a plant native to the deserts of China and Mongolia. The main active components of cistanche are phenylethanoid glycosides, echinacoside, and acteoside, which have been found to have beneficial effects on kidney health.

Kidney disease, also known as renal disease, refers to a condition in which the kidneys are not functioning properly. This can result in a buildup of waste products and toxins in the body, leading to various symptoms and complications. Cistanche may help treat kidney disease ase through several mechanisms.

Firstly, cistanche has been found to have diuretic properties, meaning it can increase urine production and help eliminate waste products from the body. This can help relieve the burden on the kidneys and prevent the buildup of toxins. By promoting diuresis, cistanche may also help Reduce high blood pressure, a common complication of kidney disease.

Moreover, cistanche has been shown to have antioxidant effects. Oxidative stress, caused by an imbalance between the production of free radicals and the body's antioxidant defenses, plays a key role in the progression of kidney disease. ies help neutralize free radicals and reduce Oxidative stress, thereby protecting the kidneys from damage. The phenylethanoid glycosides found in cistanche have been particularly effective in scavenging free radicals and inhibiting lipid peroxidation.

Additionally, cistanche has been found to have anti-inflammatory effects. Inflammation is another key factor in the development and progression of kidney disease. Cistanche's anti-inflammatory properties help reduce the production of pro-inflammatory cytokines and inhibit the activation of mandatory pathways for inflammation, thus alleviating inflammation in the kidneys.

Furthermore, cistanche has been shown to have immunomodulatory effects. In kidney disease, the immune system can be dysregulated, leading to excessive inflammation and tissue damage. Cistanche helps regulate the immune response by modulating the production and activity of immune cells, such as T cells and macrophages. This immune regulation helps reduce inflammation and prevent further damage to the kidneys.

Moreover, cistanche has been found to improve renal function by promoting the regeneration of renal tubes with cells. Renal tubular epithelial cells play a crucial role in the filtration and reabsorption of waste products and electrolytes. In kidney disease, these cells can be damaged, leading to damaged renal function. Cistanche's ability to promote the regeneration of these cells helps restore proper renal function and improve overall kidney health.

In addition to these direct effects on the kidneys, cistanche has been found to have beneficial effects on other organs and systems in the body. This holistic approach to health is particularly important in kidney disease, as the condition often affects multiple organs and systems. che has been shown to have protective effects on the liver, heart, and blood vessels, which are commonly affected by kidney disease. By promoting the health of these organs, cistanche helps improve overall kidney function and prevent further complications.

In conclusion, cistanche is a traditional Chinese herbal medicine used for centuries to treat kidney disease. Its active components have diuretic, antioxidant, anti-inflammatory, immunomodulatory, and regenerative effects, which help improve renal function and protect the kidneys from further damage. , cistanche has beneficial effects on other organs and systems, making it a holistic approach to treating kidney disease.